



Universiteit
Leiden
The Netherlands

Cardiovascular risk scores among asymptomatic adults with haemophilia

Camelo, R.M.; Caram-Deelder, C.; Duarte, B.P.; Moura, M.C.B.D.; Costa, N.C.D.; Costa, I.M.; ... ; Bom, J.V.

Citation

Camelo, R. M., Caram-Deelder, C., Duarte, B. P., Moura, M. C. B. D., Costa, N. C. D., Costa, I. M., ... Bom, J. V. (2023). Cardiovascular risk scores among asymptomatic adults with haemophilia. *Arquivos Brasileiros De Cardiologia*, 120(9). doi:10.36660/abc.20230004

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3764330>

Note: To cite this publication please use the final published version (if applicable).

Cardiovascular Risk Scores among Asymptomatic Adults with Haemophilia

Ricardo Mesquita Camelo,^{1,2,3} Camila Caram-Deelder,^{3,4} Bruna Pontes Duarte,² Marília Carolina Braga de Moura,² Neuza Cavalcanti de Moraes Costa,² Iris Maciel Costa,² Ana Maria Vanderlei,² Tania Maria Rocha Guimarães,^{2,5} Samantha Gouw,^{3,6} Suely Meireles Rezende,¹ Johanna van der Bom^{3,4}

Faculdade de Medicina, Universidade Federal de Minas Gerais,¹ Belo Horizonte, MG – Brazil

Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE),² Recife, PE – Brazil

Department of Clinical Epidemiology, Leiden University Medical Center,³ Leiden – The Netherlands

Jon J van Rood Center for Clinical Transfusion Research, Sanquin/LUMC,⁴ Leiden – The Netherlands

Faculdade de Enfermagem Nossa Senhora das Graças, Universidade de Pernambuco,⁵ Recife, PE – Brazil

Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam,⁶ Amsterdam – The Netherlands

Abstract

Background: The mortality rate of Brazilian people with haemophilia (PwH) is decreasing, but the relative incidence of deaths associated with cardiovascular disease (CVD) is increasing.

Objectives: We aimed to describe the CVD risk score of PwH according to Pooled Cohort Equations Risk (PCER) Calculator tool and its treatment recommendations. We also compared the PCER estimates with the respective Framingham Risk Score (FRS).

Methods: This cross-sectional study included male PwH ≥ 40 years treated at the Comprehensive Haemophilia Treatment Centre of Pernambuco (Recife/Brazil). PwH with a previous CVD event or a low-density lipoprotein cholesterol ≥ 5.0 mmol/L were excluded. Interviews, medical file reviews, and blood tests were performed. The PCER tool was used to estimate the CVD risk and compare it with the respective FRS. A p-value < 0.05 was accepted as statistically significant.

Results: Thirty PwH were included. Median age was 51.5 [interquartile range-IQR; 46.0-59.5] years. The prevalence of obesity, systemic arterial hypertension, diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia, and hypoHDLAemia were 20%, 67%, 24%, 14%, 47%, and 23%, respectively. The median PCER score was 6.9% [IQR; 3.1-13.2], with 50% having a high risk (PCER $\geq 7.5\%$). Statin use was suggested for 54% of PwH. Blood pressure was poorly controlled in 47% of PwH. The agreement between PCER and FRS was 80% ($\kappa = 0.60$; $p = 0.001$).

Conclusions: Half of the male people with haemophilia aged 40 years or older had a 10-year high risk of developing CVD with strong recommendations to improve control of dyslipidaemia and blood pressure.

Keywords: Hemophilia A; Hemophilia B; Primary Prevention; Heart Disease Risk Factors.

Introduction

Haemophilia is a hereditary X-linked rare bleeding disorder characterized by the reduced or absent activity of coagulation factor VIII (in haemophilia A) or factor IX (in haemophilia B).¹ In 2020, there were 209,614 people with haemophilia (PwH) worldwide, of which 165,379 had haemophilia A, 33,076 had haemophilia B, and the remaining 11,159 had unknown haemophilia type.² The most common clinical presentation of the disease is spontaneous bleeding, mainly in the joints but also in other

sites (e.g., epistaxis or central nervous system).¹ Therefore, haemophilia is considered a potentially severe disease because of its morbidities and mortality.

Factor replacement therapy provided an increase in the life expectancy of PwH.³⁻⁵ Therefore, PwH are living longer and the incidence of cardiovascular events (e.g., myocardial infarction and ischaemic stroke) is increasing.³⁻⁵ According to international guidelines, cardiovascular diseases (CVD) should be treated with antithrombotic drugs during the acute event and for secondary prevention.^{6,7} However, there are no randomized controlled trials on the optimal treatment of CVD among PwH. Physicians may base their treatments on expert opinions, balancing the risks of bleeding (due to avoiding or reducing factor replacement prophylaxis and/or prescribing anti-thrombotic medications) and clotting (due to prescribing factor replacement prophylaxis and/or avoiding anti-thrombotic medications).^{8,9} Identifying and treating CVD risk factors to prevent it may pose fewer challenges than treating a CVD event *per se* because weight control, cessation of smoking, treatments of systemic arterial


Mailing Address: Ricardo Mesquita Camelo •

Rua Lorena, 1020-101. Postal Code 30730-170, Padre Eustáquio, Belo Horizonte, MG – Brazil

E-mail: rmcameloh@hotmail.com

Manuscript received January 26, 2023, revised manuscript June 12, 2023, accepted July 17, 2023

DOI: <https://doi.org/10.36660/abc.20230004>

Central Illustration: Cardiovascular Risk Scores among Asymptomatic Adults with Haemophilia

Arq Bras Cardiol. 2023; 120(9):e20230004

Since the development of more effective and safe products to treat haemophilia, people with haemophilia are growing older. In addition, these individuals are developing cardiovascular diseases which are characteristic of ageing people. We propose that Haematologists and other clinicians that treat people with haemophilia formally and routinely evaluate cardiovascular risk factors among these individuals and, when present, the diseases should be treated according to established protocols. When required, the patients should be referred to a specialist. PCER: pooled cohort equations risk.

hypertension (SAH), diabetes mellitus (DM), and dyslipidaemia as primary prevention are not associated with increased risk of haemorrhages.

Brazil has one of the largest populations with haemophilia worldwide ($n = 13,149$).² In the last decade, after the adoption of the standard-of-care recommendations for haemophilia treatment, the life expectancy of Brazilian PwH has increased.⁵ In consequence, CVD-related mortality is proportionally increasing too.⁵ The aim of the current analysis of the HemoCardio Study was to describe the CVD risk score among PwH according to Pooled Cohort Equations Risk (PCER) Calculator tool and its treatment recommendations. A secondary analysis compared these results with the Framingham Risk Score (FRS).

Method

Study design, setting, and patient eligibility

The cross-sectional HemoCardio Study was held at the Comprehensive Haemophilia Treatment Centre of Pernambuco (CHTC-HEMOPE), in Recife/Brazil. In 2016, there were 711 PwH registered in Pernambuco state, 227 of whom were 40 years or older, and approximately 76 were followed up at the CHTC-HEMOPE.¹⁰ The study was offered to all men with haemophilia who were 30 years or older and registered at the outpatient clinic during their elective consultation at the CHTC-HEMOPE between August 1st, 2018 and July 31st, 2019, resulting in 82 participants. In the current analysis, data from men with haemophilia who were 40 years or older were used since this represents the target age group for the PCER evaluation (Central Illustration). Patients with a

history of CVD or low-density lipid cholesterol (LDLc) of 5.0 mmol/L or higher were excluded since these characteristics indicate a very high risk of CVD event in advance, and PCER calculation is not recommended for such cases.^{11,12} All data were collected using a standardized form.

Haemophilia-related data

A detailed description of the haemophilia-related data is found in the Supplemental Material.

Cardiovascular risk factor profile

A detailed description of the cardiovascular risk factor profile is found in the Supplemental Material.

Cardiovascular risk estimation tools

The PCER Calculator tool (www.cvriskcalculator.com) was used to estimate CVD 10-year risk (heart disease or stroke), assuming the person had not had a prior heart attack or stroke.^{11,12} This calculator was developed by the American College of Cardiology (ACC) and the American Heart Association (AHA), and it provides a simplified way to follow the American CVD treatment algorithm according to clinical and laboratory data and stratified risk.^{11,13-16} The variables with their respective ranges consist of age (40-79 years), gender (male/female), race (African American/other), Tc (3.4-8.3 mmol/L), HDLc (0.5-2.6 mmol/L), SBP (90-200 mmHg) and DBP (30-140 mmHg), treatment for SAH (yes/no), DM (yes/no), and smoking status (yes/no). A specific score is assigned for the value/response of each variable. The sum of these scores provides the total risk score. A person was defined as having a high risk of a 10-year

CVD event when the calculated PCER score was $\geq 7.5\%$.¹¹ Estimating CVD risk by PCER is not recommended for very high-risk people in advance, which includes patients with known CVD events (defined as a history of acute coronary syndrome, myocardial infarction, stable angina, coronary/other arterial revascularization, stroke, transient ischaemic attack, or peripheral artery disease from atherosclerosis) and people with extremely high LDLc levels (≥ 5.0 mmol/L). Therefore, the PCER tool is only appropriate for people without previous CVD events and with LDLc levels of 1.8–4.9 mmol/L.^{11,12} Finally, the PCER Calculator tool provides treatment recommendations for dyslipidaemia, blood pressure control, and CVD prevention to the 2013 ACC/AHA guideline.¹¹

The FRS tool was developed based on the predictive CVD risk of a large cohort study.^{11,15,17,18} This tool predicts the 10-year risk of major CVD events (coronary disease – chronic arterial disease, stroke, peripheral obstructive arterial disease, or heart failure).^{11,15,17,18} The following variables were inputted into a web-based calculator (http://www.zunis.org/FHS_CVD_Risk_Calc_2008.htm): age, gender, Tc, HDLc, SBP, smoking status, and treatments for SAH and DM. A specific score is assigned to a characteristic (e.g., “yes” or “no”) or a value for each variable. The sum of these points provides the CVD risk estimate of the patient. The estimated FRS for 10-year CVD events was categorised into high (> 20%), intermediate (5–20%), and low risk (< 5%). As stated by the tool,¹⁵ patients with coronary artery, cerebrovascular, or peripheral obstructive atherosclerotic disease, with subclinical (i.e., documented by diagnostic methodology) or clinical manifestations (CVD events), arterial revascularization procedures, DM, or chronic kidney disease (estimated glomerular filtration rate lower than 60 mL/min/1.73 m²) were considered as high risk in advance. Hence, we did not calculate their risk using the FRS tool. Additionally, individuals with intermediate risk, whose condition was aggravated by at least one aggravating factor, were reclassified as having high risk.¹⁵ The aggravating factors were (a) metabolic syndrome, and (b) family history of premature CVD. Finally, patients with an estimated low risk with a positive family history of premature CVD were reclassified to the intermediate risk category.¹⁸

Statistical analysis

We evaluated the existing data without performing adjustments for the missing data. Normality distribution was evaluated by the Kolmogorov–Smirnov test. Due to the small size of the population, the distributions were non-parametric. Consequently, continuous variables were expressed as medians and interquartile range (IQR). The differences between groups were evaluated by a non-parametric test (Mann–Whitney’s *U* test). Categorical variables were presented as absolute and relative (percentage) frequencies. Differences between frequencies were evaluated by Pearson’s χ^2 test. The agreement between the PCER and FRS tool was evaluated by the Cohen’s κ coefficient test. The strength of agreement was defined according to the mean κ coefficient: poor (< 0.00),

slight (0.01–0.20), fair (0.21–0.40), moderate (0.41–0.60), substantial (0.61–0.80), and almost perfect (0.81–1.00). A *p*-value < 0.05 was accepted as statistically significant for all comparisons. Data were analysed using SPSS® Statistical software, version 26 (IBM, Armonk, USA).

Results

Patient characteristics

Thirty-seven PwH were included (Figure 1). LDLc value was missing for one patient, and we considered it below 5.0 mmol/L. Two patients were excluded from the analysis due to the absence of CVD risk factor data. Five of the remaining 35 PwH were excluded because they had very high risk in advance (three had a history of CVD event, and two had extremely high levels of LDLc). Two PwH had Tc levels below the range suitable for the PCER tool, and we reconsidered them as the lowest imputable level (3.4 mmol/L). The final analysis included 30 (81%) PwH.

The median [interquartile range; IQR] age of the PwH was 51.5 [IQR; 46.0–59.5] years (Table 1). There were 12 (43%) severe PwH, 80% had haemophilia A, 57% were on prophylaxis, and 57% had current or previous HCV infection.

Cardiovascular profile

A total of six (20%) PwH were obese, and four (13%) were current smokers (Table 1). SAH was diagnosed in 67% of PwH, and 47% were on antihypertensive treatment. There were seven (24%) PwH with DM. Hypertriglyceridaemia was identified in 14% of PwH. Although no PwH was on a statin, 47% had hypercholesterolaemia, and 23% had hypoHDLAemia. Eight (29%) PwH had metabolic syndrome. No PwH was on acetylsalicylic acid (ASA) treatment.

Cardiovascular risk estimates

The median [IQR] PCER score was 6.9 [IQR; 3.1–13.2], and half of the PwH were at a high 10-year risk of CVD event (Table 1). PwH and high CVD risk on the PCER tool were older than those without high risk (*p* < 0.001). They also had higher SBP (*p* = 0.041) and SAH (*p* = 0.020) and were more frequently on antihypertensive treatment (*p* = 0.028) than PwH who did not have high risk for CVD on the PCER tool. Median fasting glycaemia (*p* = 0.002) and both the prevalence of individuals on antidiabetic treatment (*p* = 0.018) and with DM (*p* = 0.002) were higher among high-risk PCER PwH than in their counterparts. Finally, the prevalence of PwH with hypertriglyceridaemia was lower among PwH and high risk for CVD on the PCER tool than those without high risk for CVD on the PCER tool (*p* = 0.044).

There was a moderate agreement of 80% between PCER and FRS tools [κ = 0.60 ± 0.15 (95% CI; 0.31–0.89); *p* = 0.001]: 40% were considered high-risk in both tools, and 40% were considered non-high risk in both (Table 2).




Figure 1 – Patient inclusion according to the study and PCER (Pooled Cohort Equations Risk) Calculator tool criteria. Y: years; HDLc: high-density lipid cholesterol; Tc: total cholesterol; CVD: cardiovascular disease; LDLc: low-density lipid cholesterol; FRS: Framingham Risk Score.

Recommendations

Among 30 PwH, ASA and statin treatments were recommended for four (14%) and 16 (54%), respectively (Table 3). Blood pressure was poorly controlled in 14 (47%) PwH, of whom six patients were not under SAH treatment and were recommended to start it. The other eight PwH were taking antihypertensive drugs and were recommended to intensify the treatment. Three (10%) PwH were recommended ASA and high-intensity statin together with better control of their blood pressure.

Discussion

We showed that half of asymptomatic PwH who were 40 years or older had high risk of CVD events in the following 10 years, according to the PCER Calculator tool.^{11,12} Comparable results were obtained when we used the FRS tool. More importantly, half of PwH should be on statin treatment and/or should have their blood pressure treatment optimized, according to ACC/AHA guidelines.^{11,13,15} To the best of our knowledge, this is the first publication in which an online tool was used to evaluate CVD risk among PwH, adding international treatment recommendations to the final estimate.

Some of our results corroborate previous studies on CVD risk factors profile among PwH, although the prevalence seems higher for some characteristics. Biere-Rafi et al.¹⁹ evaluated CVD risk factors among 100 PwH (67% were 40 years or older, and 24% were severe). Half of their population had SAH, but very few had dyslipidaemia.¹⁹ A Dutch/British cohort of 709 PwH (ages ranging from 30 to 88 years) showed a prevalence of 49% of SAH, 15% of obesity, and 6% of DM.²⁰

Risk prediction models in CVD were designed to assess the individual risk of a first CVD event in the general population. However, important caveats must be

considered when using such risk scores. Firstly, the ACC/AHA have jointly developed the PCER Calculator tool to estimate both the 10-year and lifetime risks for developing a first CVD event.^{11,12} Participants from several large cohort studies were ultimately included for analysis and equation development.^{11,12,21} However, there may be a significant limitation when used in populations that do not resemble the source population concerning its interest, social, cultural, and ethnic characteristics (e.g., men from Recife/Brazil).^{12,21} Secondly, as expected due to the rarity, people with hereditary bleeding disorders were not enrolled in any of the referred studies,^{12,21} which could argue against its use for predicting risk in PwH, for example. Finally, it has been reported that the PCER Calculator tool systematically overestimated risks by roughly 75-150% based on its performance in five external validation cohorts.²¹ This is likely due to the use of cohort data from studies conducted over two decades ago, which may not reflect current levels of morbidity or improvements in overall health and health care since then.²¹ This suggests the need for routinely performing new external validation studies for any of these risk assessment models in contemporary cohorts to maintain model predictive value. Pennells et al.²² have recently performed such recalibration, but we did not have access to this updated document before starting the HemoCardio Study.

These drawbacks can be illustrated by the publication of van der Valk et al.²³ A lower-than-expected CVD incidence evaluated by the QRISK2-2011 score^{20,24} was found after following 579 asymptomatic PwH who were 30 years or older for five years (absolute risk reduction of 2.4%).²³ The bleeding phenotype of haemophilia may have favoured the lower incidence of CVD events. However, neither the QRISK2-2011 was validated for PwH nor the therapies to avoid CVD events (e.g., diets, exercise, antihypertensives, and statins) after the CVD risk factor evaluation were

Table 1 – Haemophilia and cardiovascular profiles and PCER estimated score

Characteristic	All patients (n = 30)	Missing	PCER < 7.5% (n = 15)	PCER ≥ 7.5% (n = 15)	p-value
Clinical data					
Age (years)	51.5 [46.0-59.5]	0	47.0 [45.0-51.0]	59 [54.0-62.0]	<0.001*
White	11/30 (37)	0	5/15 (33)	6/15 (40)	0.705†
Age at diagnosis of haemophilia (years)	18.5 [13.8-25.0]	4	15.0 [9.5-19.0]	21.0 [18.0-26.0]	0.007*
Haemophilia A	24/30 (80)	0	14/15 (93)	10/15 (67)	0.068†
Severe haemophilia	13/30 (43)	0	6/15 (40)	7/15 (47)	0.713†
Prophylaxis	17/30 (57)	0	9/15 (60)	8/15 (53)	0.713†
Inhibitor positive	2/30 (7)	0	1/15 (7)	1/15 (7)	1.000†
HIV positive	0/30 (0)	0	0/15 (0)	0/15 (0)	--
HCV positive	17/30 (57)	0	6/15 (40)	11/15 (73)	0.065†
Cardiovascular risk profile					
Waist circumference (cm)	91.5 [82.3-97.5]	2	88.5 [80.8-94.5]	92.0 [84.3-103.0]	0.329*
BMI (kg/m ²)	24.0 [22.0-27.3]	0	24.0 [22.0-26.0]	25.0 [21.0-31.0]	0.653*
Obesity	6/30 (20)	0	2/15 (13)	4/15 (27)	0.361†
Current smoker	4/30 (13)	0	1/15 (7)	3/15 (20)	0.283†
SBP (mmHg)	134.0 [116.0-140.0]	0	120.0 [112.0-136.0]	140.0 [126.0-141.0]	0.041*
DBP (mmHg)	83.5 [80.0-90.8]	0	82.0 [76.0-93.0]	86.0 [81.0-90.0]	0.713*
Antihypertensive medication	14/30 (47)	0	4/15 (27)	10/15 (67)	0.028†
SAH	20/30 (67)	0	7/15 (47)	13/15 (87)	0.020†
Glycaemia (mmol/L)	5.8 [5.1-6.5]	0	5.2 [4.9-5.8]	6.3 [5.8-11.0]	0.002*
Lowering-glucose medication	5/29 (17)	1	0/14 (0)	5/15 (33)	0.018†
Diabetes mellitus	7/29 (24)	1	0/15 (0)	7/14 (50)	0.002†
TG (mmol/L)	1.1 [0.9-1.6]	2	1.0 [0.8-2.8]	1.1 [1.0-1.5]	0.821*
Hypertriglyceridaemia	4/28 (14)	2	4/15 (27)	0/13 (0)	0.044†
Tc (mmol/L)	4.9 [4.1-6.0]	0	5.2 [4.3-6.0]	4.6 [3.6-6.0]	0.233*
Hypercholesterolaemia	14/30 (47)	0	8/15 (53)	6/15 (40)	0.464†
LDLc (mmol/L)	2.8 [2.1-3.6]	1	2.8 [2.1-3.4]	2.8 [1.8-4.0]	0.847*
HDLc (mmol/L)	1.4 [1.0-1.6]	0	1.5 [1.2-1.6]	1.3 [0.9-1.5]	0.116*
HypoHDLaemia	7/30 (23)	0	2/15 (13)	5/15 (33)	0.195†
Statin	0/29 (0)	1	0/14 (0)	0/15 (0)	--
Metabolic syndrome	8/28 (29)	2	3/14 (21)	5/15 (36)	0.403†
ASA	0/30 (0)	0	0/15 (0)	0/15 (0)	--

Continuous variables were expressed as median [interquartile range]. Frequencies were expressed as affected/total (%). *Mann-Whitney U test; †Pearson's χ^2 test. HIV: human immunodeficiency virus; HCV: hepatitis C virus; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; SAH: systemic arterial hypertension; TG: triglycerides; Tc: total cholesterol; LDLc: low-density lipid cholesterol; HDLc: high-density lipid cholesterol; ASA: acetylsalicylic acid; PCER: Pooled Cohort Equations Risk; na: not applied.

Table 2 – Agreement between cardiovascular risk estimates from Pooled Cohort Equations Risk and Framingham Risk Score tools in people with haemophilia who were 40 years or older*

	Tool		n (%)
	PCER	FRS	
Agreement			
	high risk	high risk	12/30 (40%)
	non-high risk	non-high risk	12/30 (40%)
		Total agreement	24/30 (80%)
Disagreement			
	high risk	non-high risk	3/30 (10%)
	non-high risk	high risk	3/30 (10%)
		Total disagreement	6/30 (20%)

Cohen's κ coefficient test, $\kappa = 0.60 \pm 0.15$ (95%CI, 0.31-0.89), *p*-value (Pearson's χ^2) = 0.001. *High risks of CVD in 10 years were considered as stated by the respective guidelines: risk was considered in PCER when it was $\geq 7.5\%$,¹¹ and in FRS when it was $> 20.0\%$. Risk values less than these were considered non-high risk for CVD events in 10 years.¹⁸ PCER: Pooled Cohort Equations Risk; FRS: Framingham Risk Score; CVD: cardiovascular disease.

considered. We evaluated CVD risk using both the PCER and the FRS tools.^{11,12,15,17,18} We will prospectively follow these patients to evaluate their outcomes.

Nevertheless, risk tools are widely used to promote a discussion about behavioural change and to instigate drug treatment.^{11,13,15,25} The PCER Calculator tool suggested ASA therapy for 11 (37%) PwH in HemoCardio Study, according to ACC/AHA guidelines.¹¹ There are no randomized clinical trials so far on antithrombotic safety and effectiveness for primary prevention of CVD events in PwH. The prescription of antiplatelet agents or anticoagulation should be considered by a team consisting of a cardiologist and a haematologist, together with the effective and safe administration of clotting factors.^{8,9,26} A multicentre, open, non-interventional French study compared the bleeding risk in PwH under antithrombotic therapy (both antiplatelet agents or anticoagulation) for CVD secondary prevention with PwH without antithrombotic therapy (no previous CVD event).²⁷ The bleeding risk was similar between groups, although severe bleeding occurred in both.²⁷ Nevertheless, there was no information about factor replacement during the treatments. Therefore, among PwH, balancing between anti- and pro-coagulant treatments may be challenging.

While almost half of PwH were hypercholesterolaemic and 23% were hypoHDLaemic, no patient was on statin treatment. PCER Calculator tool suggested statin treatment for 16 (54%), of whom eight should receive a high-intensity regimen.^{11,15} Indeed, there is no clinical trial on the safety of statins in PwH. A recent AHA statement on the safety and tolerability of statins posed the most effective statins could produce a

Table 3 – PCER tool recommendations for all 30 patients, according to the estimated 10-year risk score*

Recommendation	n (%)	Action needed
ASA recommendation		
No benefit	19 (63%)	No action needed
Possible benefit (consider discussing)	7 (23%)	Consider starting ASA
Benefit	4 (14%)	Start ASA
Statin recommendation		
No indication	14 (46%)	No action needed
Moderate/moderate-to-high intensity regimen	8 (27%)	Start statin
High-intensity regimen	8 (27%)	Start statin
Blood pressure recommendation		
Well-controlled 16 (53%)		
without antihypertensive drugs	10 (63%)	No action needed
with antihypertensive drugs	6 (27%)	No action needed
Poorly controlled 14 (47%)		
without antihypertensive drugs	6 (43%)	Start antihypertensive drugs
with antihypertensive drugs	8 (57%)	Adjust antihypertensive drugs
ASA benefit + high intensity regimen statin + poorly controlled blood pressure	3 (10%)	Start ASA (all 3) Start statin (all 3) Start antihypertensive drugs (1) or adjust antihypertensive drugs (2)

*Recommendations were based on the ACC/AHA guidelines.¹¹ PCER: Pooled Cohort Equations Risk; ASA: acetylsalicylic acid.

mean reduction in LDLc of 55% to 60% at the maximum dosage in the general population.²⁸ The risk of statin-induced serious muscle injury was lower than 0.1%, and the risk of serious hepatotoxicity was even lower.²⁸ In addition, although statins as secondary prevention could increase the risk of haemorrhagic stroke in people with ischaemic stroke,²⁸ this does not seem to be true for primary prevention.^{29,30} Therefore, statin treatment at moderate or high intensities seems to be a good strategy for preventing CVD events in PwH.

Of the 19 (63%) PwH who had SAH, 74% (14/19) had a poorly controlled BP, including eight PwH who were taking antihypertensive medications. There is evidence that male sex, SAH, and ageing are not only risk factors for atherothrombotic diseases,¹¹ but also risk factors for haemorrhagic stroke.³¹ Their association with a hereditary bleeding disease, mainly

when the patient is not on prophylaxis and/or is inhibitor positive,³² may significantly increase the risk of spontaneous haemorrhagic stroke. Since there are no clinical trials on antihypertensive medication's safety and effectiveness in PwH, and these drugs are not related to an increased risk of haemorrhage, we understand that PwH with uncontrolled high BP should be closely managed (e.g., behavioural changes, medication, and regular adherence verification), to normalize BP according to international guidelines.¹³

This study has several limitations. First of all, as discussed above, no population tool has been formally validated to predict individual CVD risk in PwH. Besides, there are no clinical trials on the best management of primary prevention of CVD events among PwH. In addition, ASA prescription should be cautiously discussed with other specialists (e.g., a cardiologist) on an individual basis due to the risk of bleeding events in PwH. Secondly, our results refer to a specific and small population from one single centre, which impacts the generalizability of the findings. We are currently planning a multicentre study to evaluate CVD risk in a larger population. Finally, HCV infection could have influenced the results since a recent large study showed that it is associated with a 2.5-3.5% increase in the 10-year CVD absolute risk.³³ However, this association was not confirmed by two large studies evaluating CVD risk factors and events among PwH.^{34,35}

Conclusion

In this analysis of the HemoCardio Study, the prevalence of SAH and dyslipidaemia among PwH who were 40 years or older and free from CVD was not negligible. Therefore, half of these patients had a high 10-year PCER score. Since haematologists may be the only physicians to visit PwH regularly, we support them in following the ACC/AHA guidelines for the assessment of CVD risk for primary prevention,¹¹ and we recommend them to assess traditional CVD risk factors and estimate 10-year CVD risk (PCER or FRS tools) every 4-6 years. Whenever a CVD risk is diagnosed, they can treat it and/or refer to a specialist. In such an environment, cardiologists may be significant professionals.

References

1. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. *Haemophilia*. 2020;26(Suppl 6):1-158. doi: 10.1111/hae.14046.
2. World Federation of Haemophilia. Report on the Annual Global Survey 2020 [Internet]. Montréal: WFH; 2020 [cited 2023 Aug 17]. Available from: <https://www1.wfh.org/publications/files/pdf-2045.Pdf>.
3. Larsson SA. Life Expectancy of Swedish haemophiliacs, 1831-1980. *Br J Haematol*. 1985;59(4):593-602. doi: 10.1111/j.1365-2141.1985.tb07353.x.
4. Tagliaferri A, Rivolta GF, Iorio A, Oliovocchio E, Mancuso ME, Morfini M, et al. Mortality and Causes of Death in Italian Persons with Haemophilia, 1990-2007. *Haemophilia*. 2010;16(3):437-46. doi: 10.1111/j.1365-2516.2009.02188.x.
5. Jardim LL, van der Bom JG, Caram-Deelder C, Gouw SC, Cherchiglia ML, Rezende SM. Mortality of Patients with Haemophilia in Brazil: First Report. *Haemophilia*. 2019;25(3):e146-e152. doi: 10.1111/hae.13730.
6. Levine GN, Bates ER, Bittl JA, Brindis RC, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Thorac Cardiovasc Surg*. 2016;152(5):1243-75. doi: 10.1016/j.jtcvs.2016.07.044.
7. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2019;50(12):e344-e418. doi: 10.1161/STR.0000000000000211.
8. Staritz P, Moerloose P, Schutgens R, Dolan G; ADVANCE Working Group. Applicability of the European Society of Cardiology Guidelines on Management of Acute Coronary Syndromes to People with Haemophilia

Author Contributions

Conception and design of the research: Camelo RM, Duarte BP, Vanderlei AM, Guimarães TMR; Acquisition of data: Camelo RM, Duarte BP, Moura MCB, Costa NCM, Costa IM; Analysis and interpretation of the data and Statistical analysis: Camelo RM, Caram-Deelder C; Writing of the manuscript and Critical revision of the manuscript for important intellectual content: Camelo RM, Caram-Deelder C, Duarte BP, Moura MCB, Costa NCM, Costa IM, Vanderlei AM, Guimarães TMR, Gouw S, Rezende SM, van der Bom J.

Potential conflict of interest

No potential conflict of interest relevant to this article was reported.

Sources of funding

Camelo RM received scholarship (PDSE-88881.362041/2019-1) from the CAPES Foundation, an agency under the Ministry of Education of Brazil, in order to conduct part of his doctoral research as a visiting student at Leiden University Medical Centre in the Netherlands.

Study association

This study is not associated with any thesis or dissertation work.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Fundação de Hematologia e Hemoterapia do Estado de Pernambuco under the protocol number 86067818.6.0000.5195. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.

- An Assessment by the ADVANCE Working Group. *Haemophilia*. 2013;19(6):833-40. doi: 10.1111/hae.12189.
9. Ferraris VA, Boral LI, Cohen AJ, Smyth SS, White GC 2nd. Consensus Review of the Treatment of Cardiovascular Disease in People with Hemophilia A and B. *Cardiol Rev*. 2015;23(2):53-68. doi: 10.1097/CRD.0000000000000045.
 10. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Especializada e Temática. Perfil das Coagulopatias Hereditárias. Brasília: Ministério da Saúde; 2016.
 11. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S49-73. doi: 10.1161/01.cir.0000437741.48606.98.
 12. Preiss D, Kristensen SL. The New Pooled Cohort Equations Risk Calculator. *Can J Cardiol*. 2015;31(5):613-9. doi: 10.1016/j.cjca.2015.02.001.
 13. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018;71(19):e127-e248. doi: 10.1016/j.jacc.2017.11.006.
 14. Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, Neuman A. Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. *Ann Intern Med*. 2016;164(8):542-52. doi: 10.7326/M15-3016.
 15. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. *Endocr Pract*. 2017;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL.
 16. Grundy SM, Cleeman JJ, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005;112(17):2735-52. doi: 10.1161/CIRCULATIONAHA.105.169404.
 17. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. *Circulation*. 2008;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579.
 18. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2010;56(25):e50-103. doi: 10.1016/j.jacc.2010.09.001.
 19. Biere-Rafi S, Baarslag MA, Peters M, Kruip MJ, Kraaijenhagen RA, den Heijer M, et al. Cardiovascular Risk Assessment in Haemophilia Patients. *Thromb Haemost*. 2011;105(2):274-8. doi: 10.1160/TH10-07-0460.
 20. van de Putte DEF, Fischer K, Makris M, Tait RC, Chowdary P, Collins PW, et al. Unfavourable Cardiovascular Disease Risk Profiles in a Cohort of Dutch and British Haemophilia Patients. *Thromb Haemost*. 2013;109(1):16-23. doi: 10.1160/TH12-05-0332.
 21. Wallace ML, Ricco JA, Barrett B. Screening Strategies for Cardiovascular Disease in Asymptomatic Adults. *Prim Care*. 2014;41(2):371-97. doi: 10.1016/j.pop.2014.02.010.
 22. Pennells L, Kaptoge S, Wood A, Sweeting M, Zhao X, White I, et al. Equalization of Four Cardiovascular Risk Algorithms after Systematic Recalibration: Individual-Participant Meta-Analysis of 86 Prospective Studies. *Eur Heart J*. 2019;40(7):621-31. doi: 10.1093/eurheartj/ehy653.
 23. van der Valk P, Makris M, Fischer K, Tait RC, Chowdary P, Collins PW, et al. Reduced Cardiovascular Morbidity in Patients with Hemophilia: Results of a 5-Year Multinational Prospective Study. *Blood Adv*. 2022;6(3):902-8. doi: 10.1182/bloodadvances.2021005260.
 24. Eagle K, Vaishnava P. ACP Journal Club. QRISK2-2011 Predicted Cardiovascular Disease in Adult General Practice Patients. *Ann Intern Med*. 2012;157(8):JC4-12. doi: 10.7326/0003-4819-157-8-201210160-02012.
 25. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for Cardiovascular Risk in Asymptomatic Patients. *J Am Coll Cardiol*. 2010;55(12):1169-77. doi: 10.1016/j.jacc.2009.09.066.
 26. Raucourt E, Roussel-Robert V, Zetterberg E. Prevention and Treatment of Atherosclerosis in Haemophilia - How to Balance Risk of Bleeding with Risk of Ischaemic Events. *Eur J Haematol*. 2015;94(Suppl 77):23-9. doi: 10.1111/ejh.12498.
 27. Desjonqueres A, Guillet B, Beurrier P, Pan-Petes B, Ardillon L, Pineau-Vincent F, et al. Bleeding Risk for Patients with Haemophilia Under Antithrombotic Therapy. Results of the French Multicentric Study ERHEA. *Br J Haematol*. 2019;185(4):764-7. doi: 10.1111/bjh.15606.
 28. Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2019;39(2):e38-e81. doi: 10.1161/ATV.0000000000000073.
 29. Karmali KN, Lloyd-Jones DM, Berendsen MA, Goff DC Jr, Sanghavi DM, Brown NC, et al. Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. *JAMA Cardiol*. 2016;1(3):341-9. doi: 10.1001/jamacardio.2016.0218.
 30. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse Effects of Statin Therapy: Perception vs. the Evidence - Focus on Glucose Homeostasis, Cognitive, Renal and Hepatic Function, Haemorrhagic Stroke and Cataract. *Eur Heart J*. 2018;39(27):2526-39. doi: 10.1093/eurheartj/ehy182.
 31. An SJ, Kim TJ, Yoon BW. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. *J Stroke*. 2017;19(1):3-10. doi: 10.5853/jos.2016.00864.
 32. Zanon E, Iorio A, Rocino A, Artoni A, Santoro R, Tagliaferri A, et al. Intracranial Haemorrhage in the Italian Population of Haemophilia Patients with and Without Inhibitors. *Haemophilia*. 2012;18(1):39-45. doi: 10.1111/j.1365-2516.2011.02611.x.
 33. Badawi A, Di Giuseppe G, Arora P. Cardiovascular Disease Risk in Patients with Hepatitis C Infection: Results from Two General Population Health Surveys in Canada and the United States (2007-2017). *PLoS One*. 2018;13(12):e0208839. doi: 10.1371/journal.pone.0208839.
 34. Wang JD, Chan WC, Fu YC, Tong KM, Chang ST, Hwang WL, et al. Prevalence and Risk Factors of Atherothrombotic Events among 1054 Hemophilia Patients: A Population-Based Analysis. *Thromb Res*. 2015;135(3):502-7. doi: 10.1016/j.thromres.2014.12.027.
 35. Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, et al. A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. *Blood Adv*. 2018;2(11):1325-33. doi: 10.1182/bloodadvances.2018018226.

*Supplemental Materials

For additional information, please click here.



This is an open-access article distributed under the terms of the Creative Commons Attribution License